HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Abstract
Breast cancer is one of the most common cancers in humans and will on average affect up to one in eight women in their lifetime in the United States and Europe. The Women's Health Initiative and the Million Women Study have shown that hormone replacement therapy is associated with an increased risk of incident and fatal breast cancer. In particular, synthetic progesterone derivatives (progestins) such as medroxyprogesterone acetate (MPA), used in millions of women for hormone replacement therapy and contraceptives, markedly increase the risk of developing breast cancer. Here we show that the in vivo administration of MPA triggers massive induction of the key osteoclast differentiation factor RANKL (receptor activator of NF-κB ligand) in mammary-gland epithelial cells. Genetic inactivation of the RANKL receptor RANK in mammary-gland epithelial cells prevents MPA-induced epithelial proliferation, impairs expansion of the CD49f(hi) stem-cell-enriched population, and sensitizes these cells to DNA-damage-induced cell death. Deletion of RANK from the mammary epithelium results in a markedly decreased incidence and delayed onset of MPA-driven mammary cancer. These data show that the RANKL/RANK system controls the incidence and onset of progestin-driven breast cancer.
AuthorsDaniel Schramek, Andreas Leibbrandt, Verena Sigl, Lukas Kenner, John A Pospisilik, Heather J Lee, Reiko Hanada, Purna A Joshi, Antonios Aliprantis, Laurie Glimcher, Manolis Pasparakis, Rama Khokha, Christopher J Ormandy, Martin Widschwendter, Georg Schett, Josef M Penninger
JournalNature (Nature) Vol. 468 Issue 7320 Pg. 98-102 (Nov 04 2010) ISSN: 1476-4687 [Electronic] England
PMID20881962 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Integrin alpha6
  • NF-kappa B
  • Phosphoproteins
  • Progestins
  • RANK Ligand
  • Receptor Activator of Nuclear Factor-kappa B
  • Tnfrsf11a protein, mouse
  • Tnfsf11 protein, mouse
  • Medroxyprogesterone Acetate
Topics
  • Animals
  • Apoptosis (radiation effects)
  • Cell Differentiation
  • Cell Proliferation (drug effects)
  • DNA Damage
  • Epithelial Cells (cytology, drug effects, metabolism, radiation effects)
  • Female
  • Gamma Rays
  • Integrin alpha6 (metabolism)
  • Mammary Neoplasms, Experimental (chemically induced, genetics, metabolism, pathology)
  • Medroxyprogesterone Acetate (administration & dosage, adverse effects)
  • Mice
  • NF-kappa B (metabolism)
  • Osteoclasts (cytology)
  • Phosphoproteins (analysis, immunology)
  • Progestins (administration & dosage, adverse effects)
  • RANK Ligand (deficiency, genetics, metabolism)
  • Receptor Activator of Nuclear Factor-kappa B (deficiency, genetics, metabolism)
  • Signal Transduction
  • Stem Cells (cytology, drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: